<DOC>
	<DOC>NCT00708812</DOC>
	<brief_summary>In this randomized, double-blind, placebo-controlled, multicentre trial, 126 patients between July 5, 2007 and July 30, 2008 were enrolled from 10 centers. The leader units are Shanghai Chest Hospital Affiliated to Shanghai Jiao-Tong University and Shanghai Changzheng Hospital. All eligible patients received 1 cycle (21 days) of TC chemotherapy. After chemotherapy, patients evaluated as SD (Stable Disease) or above were randomized to receive endostar plus TC or TC alone for 3 cycles, 21 days as one cycle.</brief_summary>
	<brief_title>Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>histologically or cytologically confirmed, previously untreated stage IIIB or IV NSCLC age of 1875 years at least one measurable lesion (RECIST) patients evaluated as SD or above after 1 cycle (21 days) of TC chemotherapy . adequate hematologic, cardiac, renal, and hepatic function ECOG PS 02 symptomatic brain metastases bone metastases with complications major organ dysfunction bleeding diathesis or coagulopathy pregnant or lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>Endostar</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
</DOC>